Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA4 | P22459 | 1/20 | 0.33 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.33 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8655835 | 0.74 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1MEN1CYP2C19 | |
| SCHEMBL6155288 | 0.71 | KCNA4 (0.45) | KCNA4KCNA1KCNAB1MEN1CYP2C19 | |
| SCHEMBL5983432 | 0.71 | KCNA4 (0.38) | KCNA4KCNA1KCNAB1MEN1CYP2C19 | |
| SCHEMBL2422556 | 0.71 | KCNA4 (0.38) | KCNA4KCNA1KCNAB1MEN1CYP2C19 | |
| Bicarbonate SCHEMBL21906198 | 0.70 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1MEN1CYP2C19 | |
| SCHEMBL3389675 | 0.69 | KCNA4 (0.36) | KCNA4KCNA1KCNAB1MEN1CYP2C19 | |
| SCHEMBL5785392 | 0.67 | KCNA4 (0.35) | KCNA4KCNA1KCNAB1MEN1CYP2C19 | |
| SCHEMBL6903379 | 0.67 | MEN1 (0.36) | KCNA4KCNA1KCNAB1MEN1CYP2C19 | |
| SCHEMBL9262727 | 0.66 | SLC10A2 (0.32) | — | |
| SCHEMBL1577842 | 0.64 | HTR2A (0.41) | MEN1CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| US-7528157-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7507754-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2009-03-24 | — | — | US | disclosed |
| EP-1603893-B1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2008-05-21 | — | — | EP | disclosed |
| US-20080039502-A1 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK ACQUISITION LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-7196089-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1603893-A1 | EP4 RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20040192767-A1 | EP4 receptor antagonists | ASTERAND UK ACQUISITION LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | KCNA4 497/4885KCNA1 1512/4885KCNAB1 1663/4885 |
| US-20040192767-A1 | EP4 receptor antagonists | PTGER4, PTGER1, NR4A1 | KCNA4 328/4885KCNA1 901/4885KCNAB1 1122/4885 |
| US-20070123575-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, PTGER1 | KCNA4 468/4885KCNA1 1509/4885KCNAB1 1615/4885 |
| US-20080039502-A1 | EP4 receptor antagonists | PTGER4, NR4A1, PTGER1 | KCNA4 479/4885KCNA1 1503/4885KCNAB1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.